RadNet, Inc.
RDNTRadNet, Inc.'s price has outrun its earnings. −0.9% in a year against EPS −725.0% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −0.9% in a year while annual EPS moved −725.0% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is topping out (7 weeks in) while the P/E sits at the 85th percentile of its own 3-year range. Underneath, the last four quarters read improving, and 833% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
RadNet, Inc. trades at $75.8, losing momentum at the top and 7 weeks into that stage. That is +15.1% against its own 200-day average. It sits at 75% of a 52-week range of $52 to $83. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is losing momentum at the top — week 7 of stage 3. At $75.8 it trades +15.1% versus its 200-day average and sits at 75% of its 52-week range ($52–$83).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +1,256% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
RadNet, Inc. trades at 1,823.0× P/E, at the pricey end of its own range (85th percentile). Its long-run median P/E is 184.6×, measured across 3.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 1,823.0× is at the pricey end of its own range (85th percentile), against a long-run median of 184.6× measured over 3.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −725.0% against a −0.9% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +38.5%/yr price move, ~−58.2%/yr came from earnings growth and ~+96.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
RadNet, Inc. reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 2.3% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +11.5% | +12.6% | — | — |
| Profit | −50.0% | −12.6% | — | — |
| Stock price | −0.9% | +38.5% | +21.5% | +26.9% |
4-Factor Sector Score
44.8/100 — rank 17 of 30 in Diagnostics & Research · 51% evidence confidence
RadNet, Inc. scores 44.8 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 17. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 17.8 + 9.4 + 8.6 + 9 = 44.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
RadNet, Inc. reported $0.6 B of revenue in the Mar 26 quarter, +23.4% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 11.5% a year. The last full year, FY25, came in at $2.0 B. The last four reported quarters add to $2.1 B.
FY25 revenue came in at $2.0 B (+11.5% on the year), capping 4 years at 11.5% compound. The latest quarter (Mar 26) printed $0.6 B, +23.4% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +14.9% growth against the decade's 11.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +15.0% over the last 4 quarters against +14.2%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
RadNet, Inc.'s operating margin is −3.4% in the Mar 26 quarter, +0.9 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 2.9% to 6.2%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is −3.4%, +0.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 2.9%–6.2%.
Why the margin moved: operating margin went +0.9 pp year on year while gross margin went +0.9 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
RadNet, Inc. posted a net loss of $0.02 B in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The 4-year compound rate is −15.9%. That loss is 3.4% of the quarter's revenue. The same quarter a year earlier lost $0.03 B. 2 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $0.0 B (−50.0%), and the 4-year compound rate is −15.9%.
Pace comparison, last four quarters: profit +33.3% vs revenue +14.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 833% of RadNet, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.3 B of operating cash against $0.0 B of profit. After $0.2 B of capital spending, $0.1 B was left as free cash.
FY25: operating cash of $0.3 B against reported profit of $0.0 B, leaving free cash of $0.1 B after $0.2 B of capital spending. Across the last 3 fiscal years the conversion rate is 833% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
RadNet, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 16.3% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
RadNet, Inc. earns a ROE of 2% in FY25. Return on invested capital clears the cost of that capital by −7.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.0% net margin on 0.54× asset turns.
FY25 ROE is 2%.
🚨 Why the return is what it is — the wiring (FY25): 1.0% net margin × 0.54× asset turns × 2.76× balance-sheet leverage ≈ 1.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 2.0% − 9.3% = a −7.3 pp spread. The 9.3% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
RadNet, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
RadNet, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
RadNet, Inc. carries total debt of $1.9 B against shareholder equity of $1.4 B as of Mar 26, a debt-to-equity of 1.43. On the annual view that ratio went from 4.00 in FY21 to 1.37 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $1.9 B against shareholder equity of $1.4 B — a debt-to-equity of 1.43. On the annual view, debt-to-equity went from 4.00 (FY21) to 1.37 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
15.1% of RadNet, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 13.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 15.1% of the float is sold short, and at typical trading volumes it would take about 13.8 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
RadNet, Inc.: the Z-score reads 1.77. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 1.77 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 1.77.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Labcorp Holdings Inc.LH | 62.1/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.4/35 Revenue 6.4% · PAT 31.2% · OPM change 0.9 pp 83% evidence | 14.9/25 ROCE 9.9% · OPM 12.2% 76% evidence | 16.1/20 P/E 22.9× · PEG 0.69 65% evidence | 9.7/20 RS sector -13.3% · RS bench 10% · 1Y 17%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 14.9 + 16.1 + 9.7 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Medpace Holdings, Inc.MEDP | 61.9/100Thin evidence · provisional56% evidence | BREAKING OUT | 20.5/35 Revenue — · PAT — · OPM change -0.3 pp 39% evidence | 21.3/25 ROCE 30.2% · OPM 20% 76% evidence | 10.5/20 P/E 31× · PEG — 15% evidence | 9.6/20 RS sector -13.4% · RS bench 9.2% · 1Y 23.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 21.3 + 10.5 + 9.6 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Agilent Technologies, Inc.A | 58.6/100Mixed-positive evidence81% evidence | BREAKING OUT | 22.5/35 Revenue 9.1% · PAT 21.3% · OPM change 3.7 pp 83% evidence | 15.4/25 ROCE 3.8% · OPM 21.7% 76% evidence | 14.5/20 P/E 23.2× · PEG 1.01 65% evidence | 6.2/20 RS sector -15% · RS bench 7.5% · 1Y 21.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 15.4 + 14.5 + 6.2 = 58.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Natera, Inc.NTRA | 56.6/100Mixed-positive evidence61% evidence | LEADER | 24.7/35 Revenue 37.8% · PAT — · OPM change 10.1 pp 62% evidence | 5.5/25 ROCE -4.4% · OPM -10.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.4/20 RS sector 12.2% · RS bench 40.5% · 1Y 90.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 5.5 + 10 + 16.4 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Adaptive Biotechnologies CorporationADPT | 54.7/100Thin evidence · provisional53% evidence | LEADER | 20.9/35 Revenue — · PAT — · OPM change 29.3 pp 39% evidence | 5.8/25 ROCE -3.3% · OPM -27.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.0/20 RS sector 18.8% · RS bench 48.4% · 1Y 107.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 5.8 + 10 + 18 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Quest Diagnostics IncorporatedDGX | 54.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 16.7/35 Revenue 9.9% · PAT 10.9% · OPM change -0.3 pp 83% evidence | 16.4/25 ROCE 11.1% · OPM 15.2% 76% evidence | 11.4/20 P/E 22.2× · PEG 1.75 65% evidence | 10.0/20 RS sector -8.5% · RS bench 16% · 1Y 34.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 16.4 + 11.4 + 10 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7NeoGenomics, Inc.NEO | 53.9/100Thin evidence · provisional56% evidence | LEADER | 20.2/35 Revenue — · PAT — · OPM change 6.8 pp 39% evidence | 6.0/25 ROCE -0.8% · OPM -9.8% 76% evidence | 9.0/20 P/E 134× · PEG — 15% evidence | 18.7/20 RS sector 23.4% · RS bench 53.4% · 1Y 122.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 6 + 9 + 18.7 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Charles River Laboratories International, Inc.CRL | 53.6/100Thin evidence · provisional51% evidence | LEADER | 17.4/35 Revenue 0.1% · PAT — · OPM change 4.4 pp 40% evidence | 11.8/25 ROCE 1.8% · OPM 12% 57% evidence | 8.8/20 P/E 427.2× · PEG — 15% evidence | 15.6/20 RS sector 3.3% · RS bench 29.4% · 1Y 76%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 11.8 + 8.8 + 15.6 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Revvity, Inc.RVTY | 53.3/100Thin evidence · provisional56% evidence | LEADER | 15.4/35 Revenue — · PAT — · OPM change -1.9 pp 39% evidence | 11.5/25 ROCE 0.7% · OPM 10.7% 76% evidence | 9.5/20 P/E 42.6× · PEG — 15% evidence | 16.9/20 RS sector 6.2% · RS bench 34% · 1Y 68%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 11.5 + 9.5 + 16.9 = 53.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10IQVIA Holdings Inc.IQV | 52.7/100Mixed-positive evidence81% evidence | LEADER | 12.7/35 Revenue 8.2% · PAT 6% · OPM change -1 pp 83% evidence | 13.2/25 ROCE 2.4% · OPM 11.6% 76% evidence | 12.5/20 P/E 24× · PEG 1.44 65% evidence | 14.3/20 RS sector -2.2% · RS bench 22.9% · 1Y 43.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 13.2 + 12.5 + 14.3 = 52.7 · Decision use: Price leads the evidence: RS versus the benchmark is 22.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11IDEXX Laboratories, Inc.IDXX | 52.0/100Mixed-positive evidence81% evidence | ASLEEP | 22.8/35 Revenue 12.8% · PAT 15.5% · OPM change 1.4 pp 83% evidence | 20.9/25 ROCE 20% · OPM 35% 76% evidence | 8.0/20 P/E 37× · PEG 2.01 65% evidence | 0.3/20 RS sector -38.4% · RS bench -21.6% · 1Y -21.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 20.9 + 8 + 0.3 = 52 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -38.4% and the one-year return is -21.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Illumina, Inc.ILMN | 49.5/100Mixed-negative evidence71% evidence | LEADER | 10.8/35 Revenue 4.9% · PAT -34.4% · OPM change 0.9 pp 83% evidence | 13.8/25 ROCE 5.1% · OPM 21.1% 76% evidence | 10.3/20 P/E 32.9× · PEG — 15% evidence | 14.6/20 RS sector 17.3% · RS bench 47% · 1Y 122.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 13.8 + 10.3 + 14.6 = 49.5 · Decision use: Price leads the evidence: RS versus the benchmark is 47%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Sotera Health CompanySHC | 48.3/100Thin evidence · provisional51% evidence | LEADER | 18.8/35 Revenue 7.3% · PAT 100% · OPM change 4.7 pp 40% evidence | 13.6/25 ROCE 2.6% · OPM 27.1% 57% evidence | 9.9/20 P/E 35× · PEG — 15% evidence | 6.0/20 RS sector -14.7% · RS bench 7.8% · 1Y 23.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 13.6 + 9.9 + 6 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Mettler-Toledo International Inc.MTD | 48.0/100Mixed-negative evidence81% evidence | BREAKING OUT | 17.4/35 Revenue 6.9% · PAT 9% · OPM change 2.8 pp 83% evidence | 18.5/25 ROCE 12.9% · OPM 29.8% 76% evidence | 7.6/20 P/E 28.8× · PEG 2.3 65% evidence | 4.5/20 RS sector -23.2% · RS bench -2.6% · 1Y 8.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 18.5 + 7.6 + 4.5 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Thermo Fisher Scientific Inc.TMO | 47.6/100Mixed-negative evidence81% evidence | BREAKING OUT | 14.6/35 Revenue 7.2% · PAT 6.1% · OPM change 0.9 pp 83% evidence | 16.1/25 ROCE 9.1% · OPM 18.8% 76% evidence | 5.7/20 P/E 27.4× · PEG 3.61 65% evidence | 11.2/20 RS sector -11.1% · RS bench 12.2% · 1Y 35.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 16.1 + 5.7 + 11.2 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Danaher CorporationDHR | 45.4/100Mixed-negative evidence81% evidence | BREAKING OUT | 19.5/35 Revenue 4.6% · PAT 16.9% · OPM change 5.2 pp 83% evidence | 13.3/25 ROCE 1.4% · OPM 18% 76% evidence | 9.6/20 P/E 34.8× · PEG 1.76 65% evidence | 3.0/20 RS sector -24.7% · RS bench -4.6% · 1Y 7.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 13.3 + 9.6 + 3 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17RadNet, Inc.this pageRDNT | 44.8/100Thin evidence · provisional51% evidence | BREAKING OUT | 17.8/35 Revenue 14.8% · PAT 100% · OPM change 0.9 pp 40% evidence | 9.4/25 ROCE -0.8% · OPM -4.2% 57% evidence | 8.6/20 P/E 1746× · PEG — 15% evidence | 9.0/20 RS sector -17.9% · RS bench 3.8% · 1Y -0.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 9.4 + 8.6 + 9 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Qiagen N.V.QGEN | 44.5/100Thin evidence · provisional56% evidence | BREAKING OUT | 16.3/35 Revenue 4.8% · PAT 100% · OPM change -6.8 pp 53% evidence | 12.7/25 ROCE 1.6% · OPM 17.1% 57% evidence | 11.4/20 P/E 20.9× · PEG — 15% evidence | 4.1/20 RS sector -28.4% · RS bench -9.2% · 1Y -11.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 12.7 + 11.4 + 4.1 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Guardant Health, Inc.GH | 43.1/100Thin evidence · provisional53% evidence | LEADER | 16.6/35 Revenue — · PAT — · OPM change 14.4 pp 39% evidence | 4.3/25 ROCE -9.7% · OPM -40.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.2/20 RS sector 17.1% · RS bench 46.1% · 1Y 195.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 4.3 + 10 + 12.2 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Veracyte, Inc.VCYT | 41.5/100Thin evidence · provisional56% evidence | ASLEEP | 20.5/35 Revenue — · PAT — · OPM change 13.8 pp 39% evidence | 11.0/25 ROCE 1.7% · OPM 16.3% 76% evidence | 9.7/20 P/E 41.7× · PEG — 15% evidence | 0.3/20 RS sector -30.8% · RS bench -12.6% · 1Y 12.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 11 + 9.7 + 0.3 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21ICON Public Limited CompanyICLR | 41.5/100Thin evidence · provisional56% evidence | BREAKING OUT | 14.5/35 Revenue — · PAT — · OPM change -2.8 pp 39% evidence | 10.8/25 ROCE 1% · OPM 8.5% 76% evidence | 8.9/20 P/E 310.2× · PEG — 15% evidence | 7.3/20 RS sector -15% · RS bench 6.8% · 1Y 0%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 10.8 + 8.9 + 7.3 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22GeneDx Holdings Corp.WGS | 37.7/100Thin evidence · provisional51% evidence | BREAKING OUT | 14.5/35 Revenue 33.8% · PAT — · OPM change -51 pp 40% evidence | 6.2/25 ROCE -14.4% · OPM -56.2% 57% evidence | 8.5/20 P/E 2693.5× · PEG — 15% evidence | 8.5/20 RS sector -22% · RS bench -1.9% · 1Y -24.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 6.2 + 8.5 + 8.5 = 37.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Waters CorporationWAT | 36.0/100Thin evidence · provisional58% evidence | LEADER | 11.8/35 Revenue — · PAT — · OPM change -29.2 pp 45% evidence | 8.9/25 ROCE -0.7% · OPM -5.2% 76% evidence | 9.2/20 P/E 94.6× · PEG — 15% evidence | 6.1/20 RS sector -13.8% · RS bench 8.9% · 1Y 39.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 8.9 + 9.2 + 6.1 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24BillionToOne, Inc.BLLN | 54.6/100Thin evidence · provisional31% evidence | ASLEEP | 23.0/35 Revenue 99.4% · PAT — · OPM change 20.4 pp 40% evidence | 12.3/25 ROCE 3.9% · OPM 16.5% 57% evidence | 9.3/20 P/E 60.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence |
| Exact sum: 23 + 12.3 + 9.3 + 10 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25CareDx, Inc.CDNA | 48.8/100Thin evidence · provisional50% evidence | LEADER | 15.8/35 Revenue — · PAT — · OPM change 16.8 pp 39% evidence | 4.8/25 ROCE -28.5% · OPM 1% 76% evidence | 11.5/20 P/E 13.8× · PEG — 15% evidence | 16.7/20 RS sector 67.7% · RS bench 106.8% · 1Y 267%12 of 12 weeks ahead 70% evidence |
| Exact sum: 15.8 + 4.8 + 11.5 + 16.7 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Twist Bioscience CorporationTWST | 48.5/100Thin evidence · provisional48% evidence | LEADER | 17.2/35 Revenue 17.8% · PAT — · OPM change 3.4 pp 40% evidence | 6.7/25 ROCE -8.5% · OPM -41.4% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 79.4% · RS bench 121.5% · 1Y 413%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 6.7 + 10 + 14.6 = 48.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27OPKO Health, Inc.OPK | 47.3/100Thin evidence · provisional50% evidence | TURNING | 20.3/35 Revenue — · PAT — · OPM change 3.7 pp 39% evidence | 7.2/25 ROCE -0.4% · OPM -41.1% 76% evidence | 10.2/20 P/E 33.2× · PEG — 15% evidence | 9.6/20 RS sector -10.7% · RS bench 13.2% · 1Y 11%9 of 12 weeks ahead 70% evidence |
| Exact sum: 20.3 + 7.2 + 10.2 + 9.6 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Castle Biosciences, Inc.CSTL | 45.0/100Thin evidence · provisional50% evidence | BREAKING OUT | 18.5/35 Revenue — · PAT — · OPM change 9.7 pp 39% evidence | 7.2/25 ROCE -0.6% · OPM -22% 76% evidence | 9.4/20 P/E 43× · PEG — 15% evidence | 9.9/20 RS sector -9.2% · RS bench 13.9% · 1Y 45.4%8 of 12 weeks ahead 70% evidence |
| Exact sum: 18.5 + 7.2 + 9.4 + 9.9 = 45 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Personalis, Inc.PSNL | 43.2/100Thin evidence · provisional42% evidence | LEADER | 10.9/35 Revenue -27.6% · PAT — · OPM change -122 pp 40% evidence | 5.9/25 ROCE -12.1% · OPM -207.9% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.4/20 RS sector 24.5% · RS bench 54.1% · 1Y 164.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 10.9 + 5.9 + 10 + 16.4 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30GRAIL, Inc.GRAL | 38.3/100Thin evidence · provisional48% evidence | LEADER | 20.0/35 Revenue 19.9% · PAT — · OPM change 149.6 pp 40% evidence | 6.4/25 ROCE -4.9% · OPM -332.9% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.9/20 RS sector -23.6% · RS bench -4.1% · 1Y 80.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 6.4 + 10 + 1.9 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is RadNet, Inc.'s stock price today?
RadNet, Inc. trades at $75.8, −0.9% over the past year. The company is valued at $6.0 B. The stock sits at 75% of its 52-week range of $52–$83, +15.1% versus its 200-day average. On the tape, the price is topping out, 7 weeks in. — as of 17 September 2026.
What were RadNet, Inc.'s latest quarterly results?
RadNet, Inc. reported revenue of $0.6 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.43. The operating margin was −3.4%, 0.9 pp higher than a year earlier. — as of 17 September 2026.
What is RadNet, Inc.'s revenue?
RadNet, Inc. reported revenue of $0.6 B in the Mar 26 quarter, +23.4% year on year. For the full FY25 fiscal year, revenue was $2.0 B (+11.5%). Over the last 4 years revenue compounded at 11.5% a year. — as of 17 September 2026.
What is RadNet, Inc.'s profit?
RadNet, Inc. earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran −3.4% in the latest quarter. — as of 17 September 2026.
What is RadNet, Inc.'s market cap?
RadNet, Inc.'s market capitalisation is $6.0 B at a stock price of $75.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is RadNet, Inc.'s P/E ratio?
RadNet, Inc. trades at a P/E of 1,823.0×, at the 85th percentile of its own 3-year range, against a long-run median of 184.6×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does RadNet, Inc. pay a dividend?
No — RadNet, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is RadNet, Inc. overvalued?
On its own history, RadNet, Inc. looks expensive: its P/E of 1,823.0× sits at the 85th percentile of its 3-year range (long-run median 184.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
How is RadNet, Inc. performing?
RadNet, Inc. is topping out, 7 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is RadNet, Inc. in?
Mixed — no clean majority across the growth curves, ROCE holding at 2.3% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +15.0% latest, profit growth −75.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is RadNet, Inc. in an uptrend?
It is stalling — the price is topping out (week 7 of stage 3), trading +15.1% versus its 200-day average and at 75% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is RadNet, Inc. beating the market?
On recent form, yes — RadNet, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +1,256% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.
Will RadNet, Inc.'s stock price go up?
This page publishes no price forecast for RadNet, Inc. What it measures instead: the stock price is $75.8, the price is topping out 7 weeks in. Its P/E of 1,823.0× sits at the 85th percentile of its own 3-year range. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against RadNet, Inc.?
Yes — short interest is 15.1% of RadNet, Inc.'s tradable float, about 13.8 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does RadNet, Inc. have too much debt?
It carries real leverage — RadNet, Inc.'s debt-to-equity is 1.57. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is RadNet, Inc.'s capex?
RadNet, Inc. spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.2 B. — as of 17 September 2026.
What is RadNet, Inc.'s cash flow?
RadNet, Inc. generated $0.3 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.2 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is RadNet, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 833% of RadNet, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.3 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is RadNet, Inc.?
On the balance sheet, the Z-score reads 1.77 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 17 September 2026.
Where is RadNet, Inc. in its business cycle?
RadNet, Inc.'s FY25 operating margin was 2.9%, against a 5-year band of 2.9%–6.2%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran −3.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the RadNet, Inc. story?
The sharpest disagreement: the price moved −0.9% in a year while annual EPS moved −725.0% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is RadNet, Inc. a stock worth studying right now?
This is not investment advice. The machine read: RadNet, Inc.'s price has outrun its earnings. −0.9% in a year against EPS −725.0% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!